TScan Therapeutics, Inc.
TCRX
$1.05
-$0.08-7.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.57M | 2.51M | 3.08M | 2.17M | 665.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57M | 2.51M | 3.08M | 2.17M | 665.00K |
| Cost of Revenue | 18.44M | 31.69M | 32.63M | 29.79M | 29.35M |
| Gross Profit | -15.87M | -29.18M | -29.56M | -27.62M | -28.69M |
| SG&A Expenses | 5.99M | 7.87M | 9.10M | 8.63M | 8.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.43M | 39.56M | 41.73M | 38.42M | 37.38M |
| Operating Income | -21.86M | -37.05M | -38.65M | -36.25M | -36.71M |
| Income Before Tax | -22.98M | -35.71M | -36.95M | -34.13M | -35.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.98M | -35.71M | -36.95M | -34.13M | -35.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.98M | -35.71M | -36.95M | -34.13M | -35.81M |
| EBIT | -21.86M | -37.05M | -38.65M | -36.25M | -36.71M |
| EBITDA | -21.14M | -36.29M | -37.96M | -35.57M | -36.00M |
| EPS Basic | -0.18 | -0.63 | -0.65 | -0.60 | -0.63 |
| Normalized Basic EPS | -0.10 | -0.39 | -0.41 | -0.38 | -0.38 |
| EPS Diluted | -0.18 | -0.63 | -0.65 | -0.60 | -0.63 |
| Normalized Diluted EPS | -0.10 | -0.39 | -0.41 | -0.38 | -0.38 |
| Average Basic Shares Outstanding | 129.86M | 56.75M | 56.75M | 56.59M | 56.59M |
| Average Diluted Shares Outstanding | 129.86M | 56.75M | 56.75M | 56.59M | 56.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |